BioSante Featured on TheStreet.com TV
2008-07-24 14:53:02 -
- McKinney/Chicago Alan Zachary (312) 944-6784 ext. 316 or Investor Relations: The Investor Relations Group Investors: Adam S. Holdsworth / Erica Ruderman 212-825-3210 or Media: Laura Colontrelle / Janet Vasquez 212-825-3210 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announces that its CEO, Stephen M. Simes, was interviewed by the "TheStreet.com" and featured on the "TheStreet.com" website.
The interview can be viewed on "TheStreet.com" website at: www.thestreet.com/video/10429991/index.html?puc=lhhome
Gregg Greenberg interviews Mr. Simes and discusses the development program for LibiGel(R) (testosterone gel), the market potential for the product, and partnering opportunities. BioSante currently is conducting three Phase III clinical trials for LibiGel. In a completed LibiGel Phase II clinical trial, LibiGel therapy resulted in a 238 percent increase in the number of satisfying sexual events. Today in the U.S. there is no FDA approved pharmaceutical product available for the treatment of Female Sexual Dysfunction (FSD) or Hypoactive Sexual Desire Disorder (HSDD) even though men have had several choices for years. BioSante believes LibiGel may be the first FDA approved treatment for FSD, specifically HSDD, in menopausal women in the U.S.
Additional information is available online at: www.biosantepharma.com.
About LibiGel(R)
LibiGel is a gel formulation of testosterone designed to be quickly absorbed through the skin after application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
According to a study published in the Journal of the American Medical Association, 43 percent of American women (about 40 million) experience some degree of impaired sexual function. Among the more than 1,400 women surveyed, 32 percent lacked interest in sex and 26 percent could not experience orgasm. According to IMS data, 2.0 million testosterone prescriptions were written off-label for women by U.S. physicians in 2007. The majority of women with FSD are postmenopausal, experiencing FSD due to hormonal changes following menopause, whether natural or surgical.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook(TM)). Additional information is available online at: www.biosantepharma.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as "will," "potential", "could," "can," "intends," "continue," "plans," "expects" or comparable terminology, are forward-looking statements. Examples of forward-looking statements in this news release include statements regarding the expected timing of the initiation of clinical trials and the submission of regulatory applications. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, the success of clinical testing, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Stephen M. Simes, CEO, Highlights Development Program for LibiGel
"BioSante Seeks 'Female Viagra' Breakthrough" Link Provided
